Prostate embolization for patients with symptomatic benign prostate hyperplasia: a prospective, single arm cohort study.
Recruiting
- Conditions
- benign prostate hyperplasia, BPH.
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 25
Inclusion Criteria
men > 40 years, with LUTS due to BPH, refrectory to medical therapy, Size > 50cc, IPSS > 18, Qol>2, Qmax<12.
Exclusion Criteria
malignancy prostate or bladder, neurogenic bladder, diverticula/calculi, urethra strictures, dysfunction bladderneck, eGRF < 30, prostatits, cystitis, atherosclerosis AII, allergy to i.v. contrast
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie prostate embolization's efficacy in benign prostate hyperplasia (BPH)?
How does prostate artery embolization compare to alpha-blockers and 5-alpha reductase inhibitors in BPH treatment outcomes?
Are there specific biomarkers that predict response to prostate embolization in patients with BPH?
What are the potential adverse events associated with prostate embolization for BPH and how are they managed?
What are the current investigational agents or combination therapies being explored alongside prostate embolization for BPH treatment?